Immunotherapy in non-small-cell lung cancer: new data support its use, but some challenges remain

Allan Ramos-Esquivel^{1

2}

Affiliations

¹ Departamento de Farmacologia. Escuela de Medicina, Universidad de Costa Rica, San José, Costa Rica allan.ramos@ucr.ac.cr.
² Servicio de Oncología Médica, Hospital San Juan de Dios. Caja Costarricense de Seguro Social, San José, Costa Rica.

Editorial

Allan Ramos-Esquivel. Thorax. 2022 Dec.

. 2022 Dec;77(12):1159-1160.

doi: 10.1136/thorax-2022-219472. Epub 2022 Sep 1.

Allan Ramos-Esquivel^{1

2}

¹ Departamento de Farmacologia. Escuela de Medicina, Universidad de Costa Rica, San José, Costa Rica allan.ramos@ucr.ac.cr.
² Servicio de Oncología Médica, Hospital San Juan de Dios. Caja Costarricense de Seguro Social, San José, Costa Rica.

No abstract available

Keywords: lung cancer; non-small cell lung cancer.

Conflict of interest statement

Competing interests: None declared.

Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review.
Kanabar SS, Tiwari A, Soran V, Balendran P, Price M, Turner AM. Kanabar SS, et al. Thorax. 2022 Dec;77(12):1163-1174. doi: 10.1136/thoraxjnl-2020-215614. Epub 2022 Jun 10. Thorax. 2022. PMID: 35688624